We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serological responses to revaccination against HBV in HIV‐positive patients born in the era of nationwide neonatal HBV vaccination.
- Authors
Huang, Yi‐Chia; Hsieh, Szu‐Min; Sheng, Wang‐Huei; Huang, Yu‐Shan; Lin, Kuan‐Yin; Chen, Guan‐Jhou; Yang, Shang‐Ping; Liu, Wen‐Chun; Su, Yi‐Ching; Sun, Hsin‐Yun; Hung, Chien‐Ching; Chang, Shan‐Chwen
- Abstract
Background: Serological responses to revaccination against hepatitis B virus (HBV) are unclear in HIV‐positive adults who had undergone neonatal HBV vaccination and whose antibodies against HBV had waned in the era of combination antiretroviral therapy (cART). Methods: Between 2000 and 2017, 666 HIV‐positive men who have sex with men (MSM) who were born after 1986, when nationwide neonatal HBV vaccination programme was implemented in Taiwan, were included for analyses. A serological response was defined when a hepatitis B surface antibody (anti‐HBs) titre ≥10 mIU/mL was measured 4‐24 weeks after the third dose of HBV vaccination. Results: During the study period, 295 (48.7%) HIV‐positive MSM (mean age, 23.2 years) who had lost HBV seroprotection were eligible for revaccination; 171 (58.0%) received at least 1 dose (20‐μg) of HBV vaccine and 116 (39.3%) completed the 3‐dose schedule. The serological response rate to 3 doses of HBV revaccination was 74.0% and the rate of high‐titre response (anti‐HBs titre ≥100 mIU/mL) was 46.0%. The CD4 count before the first dose (per 50‐cell/μL increment, adjusted odds ratio, 1.14; 95% confidence interval, 1.01‐1.29) was positively associated with the serological response. The incident rate of HBV infection was 9.2 per 1000 person‐years of follow‐up among the patients who were non‐responders after revaccination. Conclusions: Despite HBV vaccination in the neonatal period, the serological response rate to HBV revaccination in HIV‐positive MSM was modest and could wane rapidly. Regular testing of anti‐HBs should be integrated into the HIV care despite cART containing HBV‐active agents.
- Subjects
HEPATITIS B virus; ANTIRETROVIRAL agents; VACCINATION; IMMUNOGLOBULINS; CD4 antigen
- Publication
Liver International, 2018, Vol 38, Issue 11, p1920
- ISSN
1478-3223
- Publication type
Article
- DOI
10.1111/liv.13721